UH3DA058304

Developing a U.S. national cohort to improve virologic suppression among stimulant-using men living with HIV.

A resurgent stimulant epidemic among men living with HIV could compromise the U.S. Ending the HIV Epidemic (EHE) goals by interfering with HIV care engagement, adherence, and virologic suppression among men living with HIV.

Prominent multi-level factors interfere with HIV virologic suppression for men living with HIV, particularly among those who use stimulants.

We will digitally recruit at least 1,000 men living with HIV to identify multi-level determinants of HIV care engagement, adherence, and virologic suppression, and will recruit men living with HIV with and without stimulant use.

Guided by the social ecological model, we will investigate network factors (i.e. number of friends living with HIV), geospatial determinants (stimulant use prevalence, EHE region), and other factors that affect virologic suppression (Aim 1).

After recruitment milestones are met, we will perform a nested randomized clinical trial to test a multi-component intervention to improve virologic suppression, adherence, and stimulant use among men living with HIV who use stimulants (N=300).

The intervention, known as RESTART, will combine an evidence-based positive affect intervention delivered through a smartphone app and use of urine point-of-care testing to perform adherence self-monitoring, with motivational messages to improve or maintain adherence delivered via the RESTART app (Aim 2).

In Aim 3 of the proposal, we will assess the impact of RESTART on incremental cost per person on virologic suppression and stimulant use intensity as measured by hair stimulant levels.

By this high-impact study’s end, we will have identified multi-level determinants of the treatment continuum among digitally recruited men living with HIV, including among those who use stimulants; and the impact of a multi-component RESTART mHealth intervention using novel point-of-care adherence self-monitoring on HIV virologic suppression, stimulant use, and cost.

San Francisco Regents Of The University Of California

TO SUPPORT BASIC, CLINICAL, TRANSLATIONAL, AND IMPLEMENTATION RESEARCH IN THE FIELD OF SUBSTANCE USE. TO DEVELOP NEW KNOWLEDGE AND APPROACHES FOR THE PREVENTION, DIAGNOSIS, AND TREATMENT OF DRUG USE, MISUSE, AND ADDICTION, DRUG OVERDOSE, AND RELATED HEALTH OUTCOME, INCLUDING HIV/AIDS. TO SUPPORT RESEARCH TRAINING AND RESEARCH SCIENTIST DEVELOPMENT. TO SUPPORT DISSEMINATION OF RESEARCH FINDINGS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) LEGISLATION IS INTENDED TO EXPAND AND IMPROVE THE SBIR PROGRAMS TO EMPHASIZE AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF TECHNOLOGY DEVELOPED THROUGH FEDERAL SBIR RESEARCH AND DEVELOPMENT; INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT; AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN THE SBIR PROGRAM. THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) LEGISTLATION IS INTENDED TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS; FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS; INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT; AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.

93.279 - Drug Abuse and Addiction Research Programs

National Institute on Drug Abuse (NIDA) [HHS - NIH]

San Francisco, California 941102859 United States

Single Zip Code

Limited Interaction Targeted Epidemiology: Viral Suppression (LITE-VS) (UG3/UH3 Clinical Trial Optional) (RFA-AI-22-024)

Amendment Since initial award the total obligations have increased 279% from $953,735 to $3,616,153.